Alphamab's bispecific checkpoint antibody enters clinic in Australia, Chinese trials planned

By Elizabeth S. Eaton | Oct 12, 2018 | 6:16 PM GMT

Alphamab Oncology (Suzhou, China) started an Australian Phase I trial of KN046 to treat

Read the full 140 word article

User Sign In